Zimbabwe Pharmaceuticals and Healthcare Report Q3 2008
Business Monitor International, September 2008, Pages: 63
BMI's Zimbabwe Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Zimbabwe's pharmaceuticals and healthcare industry.
Zimbabwe’s pharmaceutical market remains an extremely unattractive prospect due to ongoing political and economic problems. Indeed, the problems breed uncertainty that makes long-term market forecasts challenging. BMI expects further slow deterioration of the market through to 2010. We believe that the market will continue to be propped up to a large extent by donations from international aid agencies, meaning that it has little further to fall. Having said this, recent threats to clamp down on international aid agency activity by the regime of President Robert Mugabe or the possible imposition of international sanctions backed by the US and UK could precipitate a further fall in the value of the pharmaceutical market.
Demonstrating the ongoing supply chain difficulties, in April 2008, Zimbabwe’s leading health insurance organisation Cimas suspended its HIV/AIDS drug benefits for those covered by the add-on chronic disease package, citing a shortage of antiretrovirals (ARVs). The insurer claimed it was unable to source ARVs from abroad due to a lack of foreign currency. Meanwhile, its local manufacturing partners had stopped producing the drugs due to pricing controls. Such a situation is likely to have a serious adverse effect on the country’s HIV/AIDS burden. BMI’s Burden of Disease Database (BoDD) forecasts that the number of disability-adjusted life years (DALYs) lost to HIV/AIDS will increase by an average of 1.4% a year between 2007 and 2012 to reach 4.92mn in 2012.
Unsurprisingly, BMI rates Zimbabwe’s business environment as the least attractive of the 13 Middle East and Africa (MEA) pharmaceutical markets surveyed. The business environment has continued to deteriorate over the past year, with the international community, led by the US and UK, looking seriously at imposing sanctions on the Mugabe regime. Meanwhile, in October 2007, Zimbabwe's parliament passed the Indigenisation and Empowerment Bill, which aims to increase local ownership of companies. The bill extends and formalises the controversial land reforms pursued by the Mugabe regime in the agricultural sector. It requires that at least 50% of shares in the manufacturing industry be owned by Zimbabweans. However, uncertainty again plagues the proposals, with no clear timescale set out for the implementation of the bill's objectives.
In April 2008, Indian backer Shreya Life Sciences divested its 40% stake in CAPS Pharmaceuticals (co-owned with CAPS Holdings) to an unnamed foreign investor. CAPS Holdings is continuing its investment in capital projects. However, the loss of its Indian backer is likely to make it challenging to obtain hard currency to fund such activities.
Executive Summary
Zimbabwe Pharmaceuticals And Healthcare Industry SWOT
Zimbabwe Political SWOT
Zimbabwe Economic SWOT
Zimbabwe Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Middle East And Africa Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Public Drug Procurement
Industry Developments
Health Profile
HIV/AIDS Situation
Healthcare System
Healthcare Funding
Healthcare Staff
Pharmaceutical Sector
Timeline Of Zimbabwe's Hyperinflation
Recent Pharmaceutical Sector Developments
Table: ARV Prices Available Through Direct Purchase From Roche (CHF)
Traditional Medicine
Biotechnology Sector Developments
Industry Forecast Scenario
Overall Market Forecasts
Table: Zimbabwe’s Drug Market Forecasts
Key Growth Factors – Industry
Table: Zimbabwe’s Healthcare Expenditure Indicators
Key Growth Factors – Macroeconomic
Table: Zimbabwe – Economic Activity
Prescription Market Forecast
Table: Zimbabwe’s Prescription Drug Market, 2005-2012 (US$mn unless otherwise stated)
OTC Market Forecast
Table: Zimbabwe’s OTC Market, 2005-2012 (US$mn unless otherwise stated)
Generics And Patented Market Forecast
Table: Zimbabwe Generics And Patented Market, 2005-2
Export/Import Forecasts
Table: Zimbabwe’s Pharmaceutical Imports And Exports, 2005-2010 (US$mn)
Other Healthcare Data Forecasts
Table: Zimbabwe’s Other Healthcare Forecasts, 2005-2012
Key Risks To BMI Forecasts
Competitive Landscape
Company Profiles
Multinational Companies
Ranbaxy
Pfizer
Novartis
Sanofi-Aventis
Merck & Co
GlaxoSmithKline
Indigenous Companies
Datlabs
Varichem Laboratories
CAPS Holdings
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
-Ranbaxy
-Pfizer
-Novartis
-Sanofi-Aventis
-Merck & Co
-GlaxoSmithKline
-Datlabs
-Varichem Laboratories
-CAPS Holdings
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Also available
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
